RAPT Therapeutics, Inc. Stock Research

Market Summary

USD17.45-0.59

Market Closed

-3.27%

RAPT Alerts

1 major insider buys and 1 major insider sales recently.

RAPT Stock Price

RAPT RSI Chart

RAPT Valuation

Market Cap

587.8M

Price/Earnings (Trailing)

-7.01

Price/Sales (Trailing)

384.93

EV/EBITDA

-7.98

Price/Free Cashflow

-8.2

RAPT Price/Sales (Trailing)

RAPT Profitability

EBT Margin

-2130.01%

Return on Equity

-41.63%

Return on Assets

-37.62%

Free Cashflow Yield

-12.19%

RAPT Fundamentals

RAPT Revenue

Revenue (TTM)

1.5M

Revenue Y/Y

-100%

Revenue Q/Q

-100%

RAPT Earnings

Earnings (TTM)

-83.8M

Earnings Y/Y

-27.8%

Earnings Q/Q

-7.9%

Price Action

52 Week Range

9.8632.45

(Low)(High)

Last 7 days

-9.5%

Last 30 days

-39.9%

Last 90 days

1.7%

Trailing 12 Months

-25.5%

RAPT Financial Health

Current Ratio

14.27

RAPT Investor Care

Shares Dilution (1Y)

14.22%

Diluted EPS (TTM)

-2.55

Peers (Alternatives to RAPT Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	298.0B	1.4B	-3.25%	8.54%	-148.7	210.43	20.37%	-37.45%
ABBV	279.9B	58.1B	4.88%	1.38%	23.64	4.82	3.30%	2.55%
REGN	87.7B	12.2B	9.61%	20.63%	20.21	7.2	-24.26%	-46.28%
VRTX	80.8B	8.9B	6.80%	24.91%	24.32	9.05	17.91%	41.84%
ALNY	23.5B	1.0B	-5.53%	16.05%	-20.81	22.69	22.88%	-32.64%
SRPT	11.5B	933.0M	2.93%	61.85%	-16.28	12.27	32.93%	-67.99%
UTHR	10.1B	1.9B	-9.77%	22.96%	13.92	5.23	14.88%	52.86%
MID-CAP
MDGL	4.2B	504.0K	-19.59%	144.55%	-14.38	2.5K	-66.53%	-22.12%
RARE	2.6B	363.3M	-18.37%	-45.49%	-3.74	7.28	3.39%	-55.81%
BPMC	2.6B	204.0M	1.49%	-34.21%	-4.68	12.78	13.30%	13.44%
MRTX	2.3B	12.4M	-15.06%	-52.42%	-3.05	181.9	-	-27.34%
SMALL-CAP
CPRX	1.7B	214.2M	4.81%	93.98%	20.42	7.92	52.10%	110.42%
MGNX	412.2M	151.9M	1.98%	-27.23%	-3.44	2.71	96.19%	40.75%
CRBP	28.6M	-	145.52%	1270.00%	-0.67	19.11	-77.61%	7.22%
CYTK	3.1M	94.6M	-20.08%	-11.44%	-0.01	0.03	34.30%	-80.65%

Financials for RAPT Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-33.1%	1,527,000	2,283,000	3,249,000	3,232,000	3,813,000
Operating Expenses	6.9%	87,322,000	81,681,000	79,502,000	76,657,000	73,022,000
S&GA Expenses	2.5%	20,240,000	19,754,000	18,449,000	16,773,000	16,037,000
R&D Expenses	8.3%	67,082,000	61,927,000	61,053,000	59,884,000	56,985,000
EBITDA	0%	-68,312,000	-68,312,000	-	-	-
EBITDA Margin	0.5%	-21.03	-21.14	-	-	-
Earnings Before Taxes	-	-69,204,000	-	-	-	-
EBT Margin	0.5%	-21.30	-21.41	-	-	-
Net Income	-6.3%	-83,800,000	-78,816,000	-76,232,000	-73,158,000	-69,204,000
Net Income Margin	-47.1%	-34.52	-23.46	-22.64	-18.15	-
Free Cahsflow	-7.1%	-69,793,000	-65,152,000	-63,371,000	-61,781,000	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	27.1%	266	209	222	188	199
Current Assets	27.7%	253	198	210	176	193
Cash Equivalents	40.6%	39.00	28.00	57.00	32.00	24.00
Net PPE	-7.4%	3.00	3.00	3.00	3.00	3.00
Liabilities	4.3%	21.00	20.00	20.00	20.00	12.00
Current Liabilities	2.6%	14.00	14.00	13.00	12.00	10.00
Shareholder's Equity	29.5%	245	189	202	168	186
Retained Earnings	-6.7%	-367	-344	-323	-304	-284
Additional Paid-In Capital	14.7%	613	535	527	473	471
Accumulated Depreciation	2.6%	8.00	8.00	8.00	8.00	-
Shares Outstanding	8.2%	34.00	31.00	30.00	30.00	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-3.2%	-70.80	-68.60	-63.97	-62.69	-61.03
Share Based Compensation	9.1%	11.00	10.00	10.00	10.00	10.00
Cashflow From Investing	-126.2%	-45.49	-20.11	-16.69	-69.92	-81.35
Cashflow From Financing	132.5%	131	56.00	52.00	140	141

Risks for RAPT

What is the probability of a big loss on RAPT?

98.9%

Probability that RAPT Therapeutics stock will be more than 20% underwater in next one year

93.3%

Probability that RAPT Therapeutics stock will be more than 30% underwater in next one year.

84.4%

Probability that RAPT Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does RAPT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if RAPT Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for RAPT

Cumulative Returns on RAPT

2.2%

3-Year Cumulative Returns

Which funds bought or sold RAPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-02-28	Voya Investment Management LLC	sold off	-100	-239,000	-	-%
2023-02-15	Jasper Ridge Partners, L.P.	unchanged	-	-194,130	903,870	0.05%
2023-02-15	Metropolitan Life Insurance Co/NY	unchanged	-	-6,558	31,442	-%
2023-02-15	Trustees of Columbia University in the City of New York	new	-	1,453,000	1,453,000	3.00%
2023-02-15	MetLife Investment Management, LLC	unchanged	-	-58,661	273,339	-%
2023-02-15	ALLIANCEBERNSTEIN L.P.	added	9.96	-64,180	611,820	-%
2023-02-14	Bank of New York Mellon Corp	added	2.2	-309,024	1,631,980	-%
2023-02-14	ORBIMED ADVISORS LLC	unchanged	-	-5,329,810	24,771,200	0.47%
2023-02-14	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	15.36	-37,476	700,524	-%
2023-02-14	PERCEPTIVE ADVISORS LLC	added	5.01	-5,598,690	35,619,300	1.00%

Latest Funds Activity

Are funds buying RAPT calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own RAPT

No. of Funds

RAPT Alerts

1 major insider buys and 1 major insider sales recently.

RAPT Therapeutics News

Schedule 13G FIlings of RAPT Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	price t rowe associates inc /md/	9.9%	3,364,887	SC 13G/A
Feb 14, 2023	redmile group, llc	9.9%	3,679,838	SC 13G/A
Feb 14, 2023	perceptive advisors llc	5.3%	1,798,955	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 01, 2023	blackrock inc.	5.5%	1,903,525	SC 13G/A
Jan 13, 2023	column group ii, lp	4.1%	1,402,008	SC 13D/A
Jun 03, 2022	redmile group, llc	9.9%	3,199,363	SC 13G
Apr 11, 2022	fmr llc	-	0	SC 13G/A
Feb 14, 2022	perceptive advisors llc	9.9%	2,927,565	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	13.3%	3,947,685	SC 13G/A

RAPT Fair Value

RAPT Therapeutics fair value in different scenarios

The table shows the Fair Value estimates for RAPT Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	1.42 -91.86%	1.42 -91.86%	1.42 -91.86%	1.43 -91.81%	1.44 -91.75%
Current Inflation	1.42 -91.86%	1.42 -91.86%	1.42 -91.86%	1.43 -91.81%	1.44 -91.75%
Very High Inflation	1.42 -91.86%	1.42 -91.86%	1.42 -91.86%	1.43 -91.81%	1.44 -91.75%

Historical RAPT Therapeutics Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of RAPT Therapeutics

View All Filings

Date Filed	Form Type	Document
Mar 15, 2023	4	Insider Trading
Mar 14, 2023	10-K	Annual Report
Mar 14, 2023	8-K	Current Report
Mar 14, 2023	S-8	Employee Benefits Plan
Mar 13, 2023	4	Insider Trading
Mar 10, 2023	8-K	Current Report
Mar 06, 2023	4	Insider Trading
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 14, 2023	SC 13G/A	Major Ownership Report
Feb 14, 2023	SC 13G/A	Major Ownership Report

Latest Insider Trading transactions for RAPT

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-14	Robbins Wendye	bought	50,125	20.05	2,500	-
2023-03-14	Robbins Wendye	bought	47,487	18.9948	2,500	-
2023-03-07	HO WILLIAM	sold	-148,100	29.62	-5,000	chief medical officer
2023-03-03	HO WILLIAM	acquired	5,520	12.00	460	chief medical officer
2023-01-24	HO WILLIAM	sold	-150,000	30.00	-5,000	chief medical officer
2023-01-19	HO WILLIAM	sold	-127,800	25.56	-5,000	chief medical officer
2023-01-12	HO WILLIAM	acquired	23,124	9.54773	2,422	chief medical officer
2023-01-05	Brockstedt Dirk G.	sold	-16,298	21.966	-742	chief scientific officer
2022-12-29	HO WILLIAM	sold	-270,450	18.03	-15,000	chief medical officer
2022-11-28	HO WILLIAM	sold	-89,350	17.87	-5,000	chief medical officer

About RAPT Therapeutics

Brian R. Wong

www.rapt.com

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

RAPT Income Statement

2022-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 1,527	$ 3,813
Operating expenses:
Research and development	67,082	56,985
General and administrative	20,240	16,037
Total operating expenses	87,322	73,022
Loss from operations	(85,795)	(69,209)
Other income, net	1,957	5
Net loss	(83,838)	(69,204)
Other comprehensive income (loss):
Foreign currency translation gain	627	258
Unrealized loss on marketable securities	(447)	(287)
Total comprehensive loss	$ (83,658)	$ (69,233)
Net loss per share, basic	$ (2.58)	$ (2.53)
Net loss per share, diluted	$ (2.58)	$ (2.53)
Weighted average number of shares used in computing net loss per share, basic	32,540,406	27,390,326
Weighted average number of shares used in computing net loss per share, diluted	32,540,406	27,390,326

RAPT Balance Sheet

2022-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 38,946	$ 24,027
Marketable securities	210,122	165,627
Prepaid expenses and other current assets	3,626	3,319
Total current assets	252,694	192,973
Property and equipment, net	2,539	2,741
Operating lease right-of-use assets	6,940
Other assets	4,036	2,922
Total assets	266,209	198,636
Current liabilities:
Accounts payable	3,365	1,999
Accrued expenses	8,656	6,326
Deferred revenue, current		1,016
Operating lease liabilities, current	2,171
Other current liabilities	32	254
Total current liabilities	14,224	9,595
Deferred revenue, net of current portion		511
Deferred rent, net of current portion		2,150
Operating lease liabilities, non-current	6,819
Total liabilities	21,043	12,256
Commitments (see note 6)
Stockholders' equity:
Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2022 and 2021
Common stock, $0.0001 par value; 500,000,000 shares authorized;34,254,314 and 29,555,119 shares issued and outstanding at December 31, 2022 and 2021, respectively	3	3
Additional paid-in capital	613,073	470,629
Accumulated other comprehensive loss	(26)	(206)
Accumulated deficit	(367,884)	(284,046)
Total stockholders' equity	245,166	186,380
Total liabilities and stockholders' equity	$ 266,209	$ 198,636